^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LCB84

    i
    Other names: LCB84
    Company:
    J&J, LigaChem Biosci, Mediterranea Theranostic
    Drug class:
    Microtubule inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    1year
    LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial (Businesswire)
    "BostonGene...announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody)....BostonGene will serve as the study’s central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients’ tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample."
    Licensing / partnership
    |
    LCB84
    1year
    A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, LegoChem Biosciences, Inc | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    LCB84
    over1year
    Phase 1/2 Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Not yet recruiting, LegoChem Biosciences, Inc
    New P1/2 trial • Combination therapy • Metastases
    |
    LCB84